Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Debt: 2009-2025

Historic Total Debt for China Pharma Holdings (CPHI) over the last 16 years, with Sep 2025 value amounting to $2.0 million.

  • China Pharma Holdings' Total Debt fell 20.78% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1.16%. This contributed to the annual value of $2.5 million for FY2024, which is 0.38% down from last year.
  • Latest data reveals that China Pharma Holdings reported Total Debt of $2.0 million as of Q3 2025, which was down 28.29% from $2.7 million recorded in Q2 2025.
  • China Pharma Holdings' 5-year Total Debt high stood at $4.3 million for Q3 2021, and its period low was $2.0 million during Q3 2025.
  • Moreover, its 3-year median value for Total Debt was $2.5 million (2024), whereas its average is $2.5 million.
  • The largest annual percentage gain for China Pharma Holdings' Total Debt in the last 5 years was 49.52% (2022), contrasted with its biggest fall of 43.61% (2022).
  • Over the past 5 years, China Pharma Holdings' Total Debt (Quarterly) stood at $4.3 million in 2021, then crashed by 43.61% to $2.4 million in 2022, then climbed by 4.29% to $2.5 million in 2023, then decreased by 0.38% to $2.5 million in 2024, then dropped by 20.78% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.7 million for Q2 2025, and $2.5 million during Q1 2025.